Antihepcidin Antibody Treatment Modulates Iron Metabolism and Is Effective in a Mouse Model of Inflammation-Induced Anemia

January 2010 in “ Blood ”

Barbra J. Sasu, Keegan S. Cooke, Tara Arvedson, Cherylene A. Plewa, Aaron R. Ellison, Jackie Sheng, Aaron Winters, Todd Juan, Hongyan Li, C. Glenn Begley, Graham Molineux

hepcidin antihepcidin antibodies iron metabolism inflammation-induced anemia hair loss iron sequestration

Studysummary This study suggests that antihepcidin antibodies may effectively treat inflammatory anemia by manipulating iron metabolism, based on experiments conducted in mouse models and hHepc knock-in mice.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on ashpublications.org →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research Generation of an intestinal‐specific hephaestin knockout mouse

April 2010 in “The FASEB Journal”

This study found that knockout mice lacking intestinal hephaestin are smaller and anemic compared to wild-type, suggesting other mechanisms may compensate for iron absorption.

research P730 High-dosed intravenous iron replacement therapy does not hinder drug-induced amelioration of disease activity in IBD patients with iron deficiency anaemia

January 2018 in “Journal of Crohn s and Colitis”

This study found that high-dose intravenous ferric carboxymaltose may reduce inflammatory activity in patients with inflammatory bowel disease and iron deficiency anaemia, as evidenced by decreased CRP levels and improved clinical disease indices.

research High-Dosed Intravenous Iron Replacement Therapy for Iron Deficiency Anemia Does Not Hinder Drug-Induced Amelioration of Disease Activity in IBD Patients

February 2018 in “The American Journal of Gastroenterology”

This study observed that intravenous ferric carboxymaltose did not inhibit the drug-induced reduction of inflammatory activity in patients with inflammatory bowel disease, as indicated by lower CRP levels.

research P0689 High-dose IV iron safely and effectively treats IBD-associated anaemia regardless of inflammatory activity – real-life evidence from Germany

January 2026 in “Journal of Crohn s and Colitis”

This study found that high-dose intravenous iron therapy was effective and safe for patients with inflammatory bowel disease-associated anemia, improving hemoglobin and iron levels, reducing inflammation markers, and alleviating disease activity and symptoms, even in those with active inflammation.

research Matriptase-2, A Novel Suppressor of Hepcidin.

November 2009 in “Blood”

This study found that mutations in the TMPRSS6 gene affect the ability of matriptase-2 to inhibit hepcidin, which may impact the molecular pathogenesis of iron-refractory iron-deficiency anemia.